3 results match your criteria: "Department of Biomedical Sciences Humanitas University Pieve Emanuele Italy.[Affiliation]"
Incidence of blast phase in myelofibrosis according to anemia severity.
EJHaem
August 2023
Hematology Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico Milan Italy.
Article Synopsis
- Myelofibrosis (MF) is a type of blood cancer often causing anemia, which can lead to a progression to a severe form known as blast phase (BP) in 10%-20% of patients.
- In a study of 1,752 MF patients largely untreated with ruxolitinib (RUX), anemia significantly increased BP incidence, with rates varying based on the severity of anemia.
- Even among patients treated with RUX, those starting treatment with significant anemia showed similar BP rates, underscoring the need for careful management of anemia in MF patients and its implications for treatment safety.
Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis.
Clin Transl Allergy
June 2021
Personalized Medicine, Asthma and Allergy Humanitas Clinical and Research Center IRCCS Rozzano Italy.
Background: Observational comparative effectiveness studies in allergen immunotherapy (AIT) represent an important evidence source answering research questions that can be challenging to obtain from randomized controlled trials (RCTs), such as long-term benefits of AIT, the effects on asthma prevention and the onset of new allergen sensitizations. However, observational studies are prone to several sources of bias, which limit their reliability.The REal Life Evidence AssessmeNt Tool (RELEVANT) was recently developed to assist in quality appraisal of observational comparative research to enable identification of useful nonrandomized studies to be considered within guideline development.
View Article and Find Full Text PDF